Find a Condition by Name
Health & Wellness Information
Find a Doctor by Name
Departments & Divisions
Locations & Maps
Parking & Directions
Travel & Lodging
International & Out of State
Health & Wellness Tips
Patient Education & Support
Professional Education - CME/CE
Adult Clinical Trials
Pediatric Clinical Trials
See All Trials
Core Labs & Diagnostics
Tucker Medical Library
Our researchers are currently in need of adult and pediatric study participants to help us pursue better treatments and cures. Participants may receive medical evaluations and procedures, study medication, disease-related education and possible financial compensation for time, travel and participation.
What if there were specific biological markers that we could use to predict and treat severe asthma? Our researchers are trying to isolate environmental factors to see what biological markers there may be for refractory asthma.
Our researchers are trying to determine if a study medication called omalizumab alone or combined with oral immunotherapy may help people with multiple food allergies.
Anyone with hypersensitivity pneumonitis may qualify for this observational study and help researchers find patterns for predicting ILD.
This study evaluates an investigational blood test called PrismRATM that identifies patients who may not respond well to anti-TNF therapies.
Diagnosed with IPF? Participate in a research study to evaluate the effectiveness of an investigational new drug for treatment of persistent cough in patients with Idiopathic Pulmonary Fibrosis.
A new study is using a smartphone app to monitor participants’ asthma and provide personalized feedback. If you have difficult-to control asthma you may qualify for this clinical trial.
Inhaled antifungal Itraconazole may be more effective than oral medications for allergic bronchopulmonary aspergillosis (ABPA). Find out if you qualify for this clinical trial.
If you have been diagnosed with idiopathic pulmonary fibrosis within the last 5 years and are 40 or older, we may be able to help.
This is an observational study to evaluate the biological and clinical effects of triple-combination therapy (TCT), elexacaftor/tezacaftor/ivacaftor, in people with cystic fibrosis (CF) before and after starting this therapy, as prescribed by their doctor.
Researchers want to investigate lung and digestive functions in CF patients with an investigational triple combination therapy.
New study drug combines two medications known for asthma relief may help manage the symptoms of moderate to severe asthma in both children and adults.
Doctors today are still learning about the causes of asthma. With just an hour of your time, you can help our researchers look deeper into the genetics of the disease and develop better treatment options
This study is evaluating the safety and effectiveness of a new investigational medication called VX-561, an altered form of KALYDECO® (generic: ivacaftor), compared to the original ivacaftor.
National Jewish Health researchers are trying to determine why people with atopic dermatitis or eczema are more susceptible to bacterial infections. Learn how you can participate in our research study.
Does your mind race at night when you're trying to sleep? Our researchers are studying how people with insomnia and obstructive sleep apnea can benefit from cognitive behavioral therapy, a goal-oriented type of treatment that aims to identify and change inaccurate or negative thinking patterns...
Our researchers are working to identify the clinical, physiologic, genetic and molecular characteristics of asthmatics.
In addition to its impact on lung function and sweat chloride, a new medication regimen may improve chronic sinusitis signs and symptoms and sense of smell for people with CF.
By adding a new investigational Pulmonary Arterial Hypertension (PAH) medication to your current therapy, you could experience relaxed and widened artery walls.
A new investigational medication for Pulmonary Arterial Hypertension is thought to treat inflammation and lower the pressure in blood vessels from the heart to lungs.
By participating in our study, you can help forward research on lung disease. Our researchers are hoping to learn more about the blood cells involved in the development of scarring lung diseases and create new treatment therapies.
Already approved for advanced non-small cell lung cancer, atezolizumab is a drug that may help those with early-stage lung cancer, as well. Participants in this clinical trial may take atezolizumab in conjunction with their chemotherapy treatments.
Help us look at how specific white blood cells are associated with hypersensitivity pneumonitis (HP) and impact how your disease affects you.
A new study is looking at an investigational drug that stimulates immune response to fight infection. If you have cystic fibrosis and an ongoing mycobacterial infection, this trial may be right for you.
Do you have mild to moderate osteoarthritis in your knee? Our researchers are conducting a study on an FDA-approved drug that may reduce osteoarthritis knee pain and improve function.
The purpose of this study is to learn more about lung disease found in contractors and U.S. military personnel serving in Iraq and Afghanistan after September 11, 2001.
This research study evaluates an investigational medication called Acthar® Gel (Acthar) as a potential treatment of pulmonary sarcoidosis.
National Jewish Health researchers are studying a new phosphate cream that could reduce painful inflammation. Children ages 2 to 17 with atopic dermatitis may qualify. Learn more.
The purpose of this research study is to identify the general and disease-specific sexual and reproductive health concerns of women with Cystic Fibrosis (CF).
Our researchers are trying to understand the connection, as well as how to prevent and treat lung disease in RA patients.
Our researchers are trying to understand how interstitial lung disease (ILD) develops in people with rheumatoid arthritis (RA), and how it may impact their quality of life.
The purpose of this study is to measure and accurately identify the presence and severity of gastroesphageal reflux disease (GERD), commonly called acid reflux, in idiopathic pulmonary fibrosis (IPF) patients using the Supraglottic Index (SGI).
Our researchers are studying the lungs of current and former smokers to understand how to improve the diagnosis and treatment of Chronic Obstructive Pulmonary Disease (COPD), a disease that is common among smokers. You do not need to have COPD to participate in this study.
If you are an adult with sarcoidosis who is not on immunosuppressive therapy, you may be able to help our researchers learn more about different types of sarcoidosis and how it develops.
Our researchers are studying lung diseases that develop from inhaling mineral dust over time. Although the cause of diseases such as "black lung" are known, it is not well understood why some people develop these diseases and others don't.
The purpose of this study is to determine how two medications, azithromycin and inhaled tobramycin, work when taken together to treat cystic fibrosis (CF) patients with chronic pseudomonas aeruginosa (PA) lung infections.
Are you one of the many people with atopic dermatitis (eczema) who continues to have dry, itchy skin, and repeat infections that are not controlled by your medicine? Our researchers are seeking participants for a clinical trial that will test a medication called dupilumab that was recently...
Our researchers are studying an investigational combination of medications, one used to treat asthma in adults and the other not yet approved to treat adult asthma, to determine if it can improve symptoms and lung function in asthma patients age 5 to 17.
Our researchers are studying an investigational medication to determine if it improves lung function in teens with asthma. By blocking a key receptor that causes inflammation in the lungs, the medication may improve and prevent symptoms such as wheezing and shortness of breath.
Our researchers are studying glycerol phenylbutyrate (GPBA), also known as RAVICTI®, to determine how safe it is and how well people tolerate it in the treatment of cystic fibrosis (CF).
Do you have rheumatoid arthritis and interstitial lung disease (RA-ILD)? You may be able to help our researchers determine if people with RA-ILD can benefit from a medication called Pirfenidone, which has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic...
Are you 18 or older with no history of chronic lung conditions? You may be able to help our researchers better understand lung disease. Compensation provided.
The purpose of this study is to learn more about how Opsumit® (the commercial form of the medication macitentan) is used in clinical practice to treat pulmonary arterial hypertension (PAH) and other conditions.
Adults age 40 or older are needed to help our researchers determine if an investigational medication can help slow damage to the lungs in people who have COPD with emphysema.
The purpose of this study is to see if a drug called sirolimus slows development of lymphangioleiomyomatosis (LAM), a lung disease in which abnormal cells growing inside the lungs prevent them from working properly.
The purpose of this study is to gather information about treatment of early-stage lung cancer in order to compare the effectiveness of surgery versus radiation therapy, potentially improving outcomes for patients with early-stage lung cancer.
The purpose of this clinical trial is to see if it better to receive an investigational medication or no further treatment after surgery (and possibly chemotherapy) to remove non-small cell lung cancer (NSCLC).
The purpose of this clinical trial is to study the safety and potential benefits of treating fibrotic hypersensitivity pneumonitis (FHP) with an investigational medication.
If you or your child age 3 or older has atopic dermatitis (eczema), you may be able to help our researchers learn why some people with eczema have increased risk of skin infection.
The purpose of this study is to investigate inherited genetic factors that play a role in the development of familial pulmonary fibrosis and to identify a group of genes that predispose individuals to develop pulmonary fibrosis.